Merck proposal on Mevacor shot down by FDA panel

An FDA panel voted 20-3 against a proposal from Merck and Johnson & Johnson for a nonprescription, low dose version of Mevacor, part of the statin family of drugs used to lower cholesterol and heart disease risk.

The Food and Drug Administration usually follows the recommendations of the advisory panels.